Compassionate Use vs Right-to-Try: Which Pathway Could Work for You?
Share
When standard treatments are exhausted and a clinical trial isn’t an option, two important pathways may still provide access to investigational therapies: Expanded Access (commonly called compassionate use) and Right-to-Try.
What Is Compassionate Use (Expanded Access)?
Expanded Access is a pathway established by the FDA that allows a patient with a serious or immediately life-threatening condition to access an investigational drug, biologic, or device outside of a clinical trial. The FDA approves over 99% of Expanded Access requests, often within a few days.
Key requirements:
- No comparable or satisfactory approved therapy exists
- The patient cannot participate in a clinical trial
- Potential benefits justify the potential risks
What Is Right-to-Try?
The federal Right-to-Try Act (2018) allows eligible patients to access certain investigational drugs that have completed Phase 1 safety testing without going through the FDA’s Expanded Access process. The FDA’s role is limited to receiving annual reports from manufacturers.
Side-by-Side Comparison
| Aspect | Expanded Access (Compassionate Use) | Right-to-Try |
|---|---|---|
| FDA Involvement | Active review and approval (99% approval rate) | Minimal — only receives annual reports |
| Drug Stage Required | Any stage (as long as sponsor agrees) | Must have completed Phase 1 |
| Oversight & Safeguards | Full FDA + IRB review | Fewer federal safeguards |
| Physician Role | Doctor files detailed request | Doctor requests directly from manufacturer |
| Data Reporting | Safety data reported to FDA | Limited mandatory reporting |
| Usage in Practice | Used thousands of times per year | Used very rarely |
Practical Considerations for Families
- Cost: Manufacturers often provide the drug at no cost, but patients may still pay for monitoring, travel, and hospital fees.
- Time: Expanded Access can move quickly (days to weeks) once the manufacturer agrees.
- Manufacturer Willingness: This is often the biggest hurdle for both pathways — the company must be willing and able to supply the product.
- International Options: Many countries have similar compassionate-use programs with their own rules.
Understanding these differences helps families have more informed conversations with their doctors and explore every realistic option.
If you’re exploring whether compassionate use, Right-to-Try, or other pathways might apply to your situation, our independent research team offers a free case assessment. We review your records and outline clear, practical options in plain language — no obligation.